HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent.

Abstract
Antitumor activities of L-MTP-PE (Liposome entrapped myuramyl tripeptide phosphatidylethanolamine) in the combination treatment with chemo- or immune-therapeutic antitumor agents against various syngeneic tumors were tested.Against Meth A fibrosarcoma solid tumor system, L-MTP-PE showed slight but statistically significant elongation of survival days against 5-FU monotherapy in spite of its non-effect on tumor growth, when combined with 5-FU. Against liver metastasis model of M5076 carcinoma, L-MTP-PE showed a tendency of elongation of survival days by its single drug treatment, however, elongation with statistical significance was observed in the combination treatment with 5-FU in comparison with control group.These data suggest that L-MTP-PE seems to elongate the survival days of the solid tumor bearing mice and the liver metastasis model basically due to its saving effect on chemotherapeutic drug-induced immunosuppression. In the combination with an immunotherapeutic agent in mice, TNF production induced by another biological response modifier OK-432 was potentiated when primed with L-MTP-PE. L-MTP-PE also potentiate the antitumor effect of OK-432 possibly through the enhanced production of TNF-α. Combination of L-MTP-PE and OK-432 is considered to be a candidate for a new treatment model for cancer.
AuthorsMotoharu Tanaka, Shigeru Abe
JournalDrug research (Drug Res (Stuttg)) Vol. 72 Issue 7 Pg. 372-377 (Sep 2022) ISSN: 2194-9387 [Electronic] Germany
PMID35767993 (Publication Type: Journal Article)
CopyrightThieme. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Drug Carriers
  • Immunologic Factors
  • Immunomodulating Agents
  • Liposomes
  • Phosphatidylethanolamines
  • mifamurtide
  • Picibanil
  • Acetylmuramyl-Alanyl-Isoglutamine
  • Fluorouracil
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (analogs & derivatives, pharmacology, therapeutic use)
  • Adjuvants, Immunologic
  • Animals
  • Drug Carriers
  • Fluorouracil
  • Immunologic Factors
  • Immunomodulating Agents
  • Liposomes
  • Liver Neoplasms (drug therapy)
  • Mice
  • Phosphatidylethanolamines (pharmacology, therapeutic use)
  • Picibanil

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: